Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome
As an element of Nautilus’ overall reagent development and sourcing strategy, the partnership aims to accelerate research and development, and provide customers with access to Abcam’s antibody development technology and expertise Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, and Abcam (AIM:ABC; NASDAQ:ABCM), a…
